News sentiment analysis powered by sentiment-insight.com
FOCUS-Researchers return to Alzheimer's vaccines,...
Clinical trials are underway or completed for at least seven Alzheimer's vaccines. Eisai and Biogen's newly launched Leqembi and Eli Lilly's donanemab are two such treatments.
Trials of Promising Alzheimer's Vaccines Underway Clinical trials are underway or completed for at least seven Alzheimer’s vaccines. Eisai and Biogen's newly launched Leqembi and Eli Lilly's donanemab are now under U.S. regulatory review.
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024. The company said the launch of Lequembi in the United States was progressing as planned.
Eisai expects Alzheimer's drug to rake in revenue of... Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024. Jefferies analyst Michael Yee estimated the drug to generate revenue of $28 million in 2023. U.S. partner Biogen will report third-quarter results on Nov. 8.
Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggests Alzheimer’s drug Leqembi may be given as a set of two weekly shots at home. Eisai says it plans to file an application for FDA approval of the weekly shot form next year.
Japan approves Alzheimer treatment Leqembi by Eisai and... Japan's health ministry has approved Eisai's Alzheimer treatment Leqembi. The development comes after a health ministry panel recommended the drug's approval. The drug is the first treatment shown to slow progression of the disease.
Japan approves Alzheimer treatment Leqembi by Eisai and Biogen Japan's health ministry approves Eisai's Alzheimer treatment Leqembi. The drug is co-developed with U.S.-based Biogen. It is the first treatment shown to slow progression of the disease for people in the earlier stages.
Reuters Health News Summary Novo Nordisk and Valo to research cardiometabolic treatments. Novartis confirms Sandoz spin-off for October 4, 2023. Japan approves Alzheimer treatment Leqembi by Eisai and Biogen.
Japan approves Alzheimer's treatment Leqembi by Eisai... Japan's Eisai said on Monday its Alzheimer's treatment developed with Biogen, Leqembi, was approved by the country's health ministry. The drug is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's.
Keytruda Combo Therapy Fails in Lung Cancer Trials Merck and Eisai said on Friday a combination of their cancer therapies did not prolong the lives of patients in two late-stage studies. The pairing of Merck's blockbuster immunotherapy Keytruda and EIsai's Lenvima has previously failed in studies evaluating it in other cancers.
Merck, Eisai's combination therapy fails in lung cancer... Merck's Keytruda and Eisai's Lenvima failed in two late-stage studies. Pairing has failed in studies evaluating it in patients with head-and-neck cancer, skin cancer and colon cancer.
Merck, Eisai's combination therapy fails in lung cancer studies Merck's Keytruda and Eisai's Lenvima did not prolong the lives of patients in two late-stage studies testing it as a treatment for a type of lung cancer. The pairing has previously failed in studies evaluating it in patients with head-and-neck cancer, skin cancer and colon cancer.
Reuters Health News Summary Danish drugmaker Novo Nordisk aims to convince Europeans governments to pay for its obesity drug Wegovy for the most overweight or those with co-morbidities. Merck, Eisai discontinue late-stage study for combo cancer therapy. Alnylam Pharmaceuticals to appeal ruling on patents related to Moderna's COVID vaccines.
Merck, Eisai discontinue late-stage study for cancer therapy Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and neck cancer. Former President Trump tweeted for the first time in more than two years on Thursday night.
Merck, Eisai discontinue late-stage study for cancer... Merck's Keytruda in combination with Eisai's Lenvima failed to achieve statistical significance in one of the three main goals of the study.
Japanese health ministry panel recommends approval of Alzheimer's treatment Leqembi The expert panel's decision sets the stage for official approval of the drug. Leqembi was co-developed by Japan's Eisai and U.S.-based Biogen.
Japan health ministry panel recommends approval of Alzheimer's treatment Leqembi The expert panel's decision sets the stage for official approval of the drug. Leqembi is co-developed by Japan's Eisai and U.S.-based Biogen. The company expects to begin marketing the drug within about 60 days.
Few patients may qualify to get new Alzheimer’s drugs, study suggests Eisai's Leqembi and Biogen's Aduhelm are approved for older adults with mild cognitive impairment or early-stage Alzheimer's disease. Less than 1 in 10 patients at this point in the disease may be prescribed them. The estimate is based on how drugmakers studied the drugs in clinical trials.
Insurers won't cover new Alzheimer's treatment for some customers Leqembi is the first medicine that's been convincingly shown to slow the cognitive decline caused by Alzheimer's. About 76% of the people taking the drug will be covered by Medicare, according to the drugmaker Eisai.
Insurers won't cover new Alzheimer's treatment for some customers Leqembi is the first medicine that's been convincingly shown to slow the cognitive decline caused by Alzheimer's. About 76% of the people taking the drug will be covered by Medicare, according to the drugmaker Eisai.
Sign Up
